Clinical trial NCT04260529: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
Official title: A First-in-human, Open-label Dose Escalation Followed by Dose Expansion Phase I/IIa Trial to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Intratumoral CyPep-1 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Cancers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Tumor Malignancy
Keywords: Cancer
Tumour
Oncology
Immunotherapy
Oncolytic
CD8
Intratumoral
Neoplasm
Lead sponsor: Cytovation AS
Sponsor class: INDUSTRY
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2020-02-07
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors in monotherapy and in combination with anti-PD-1 antibody pembrolizumab. Additionally, the trial will monitor anti-tumor effects on both injected lesions and distant non-injected deposits.

Detailed description: Treatment with immune modulating agents may result in long lasting anti-tumor responses in patients with cancer. However, only a subset of patients obtains durable remission. Treatment strategies that aim at recruiting tumor antagonizing cellular components of the immune system holds great promise. CyPep-1 is a chemically synthesized peptide with oncolytic properties. It selectively targets cancer cells based on their altered molecular composition, and removes the surrounding cell membrane. This releases tumor neoantigens to the microenvironment and potentially induces an anti-tumour immune response.

Preclinical studies showing that CyPep-1 can synergize with anti-PD-1 antibody treatment in terms of decreased tumor volumes and prolonged survival highlight the possible clinical utility of CyPep-1 in the combination setting with ICIs.

This is a phase I/IIa, open label trial, with a dose escalation phase to evaluate the safety and tolerability of CyPep-1 as monotherapy and in combination with pembrolizumab, to identify the recommended phase 2 dose, followed by a dose expansion phase in subjects with advanced solid tumors. The trial consists of two phases and multiple arms.

Secondary objectives are preliminary anti-tumor efficacy and to assess the pharmacokinetics (PK) of CyPep-1 as monotherapy and in combination with pembrolizumab. As part of the exploratory analysis, it is planned to determine local and systemic immunological effects after CyPep-1 administration, alone and in combination with pembrolizumab.

Eligibility criteria: Inclusion criteria:

For Phase I and Phase IIa Arms A and C:

1. Histologically or cytologically confirmed locally advanced (unresectable) or metastatic tumors (solid tumor or lymphoma) with an accessible tumor lesion for intratumoral injection of CyPep-1 malignancy (including lymphomas) that is either:

   1. Refractory to standard-of-care treatment
   2. Have a disease for which there is no standard therapy considered appropriate. Metastatic deposits (including cutaneous/subcutaneous lesions and metastatic deposits in lymph nodes) of tumors for which IT injections may be performed are eligible. Pure cutaneous infiltrations (e.g., breast cancer cutaneous carcinomatosis) are ineligible.
2. 1 to 3 non-ulcerated transcutaneously accessible lesion(s) for injection and measurable as defined by iRECIST. All other tumor lesion(s) may be selected for efficacy follow-up but will not be subjected to treatment with CyPep-1.
3. Presence of tumor lesion(s) (that have not been previously irradiated) suitable for biopsy at screening and at Week 6.

   For Arm C:
4. Confirmation of the presence of at least 1 liver metastasis by imaging.
5. Subjects must have measurable disease which is equal to one or more metastatic liver lesions that can be accurately and serially measured that are greater than 1 cm dimension and for which the longest diameter is greater or equal to 1 cm as measured by CT (computed tomography)scan or magnetic resonance imaging (MRI). The metastatic liver lesion must not be in an area that received prior localized therapies.
6. Metastatic liver lesion for injection with \>50% radiological visible necrosis must be avoided and the lesion must be located where any tumor swelling will not lead to gall bladder tract obstruction or lead to bleeding risk.

   For Arm D:
7. Histologically or cytologically confirmed diagnosis of advanced (unresectable Stage III) or metastatic (Stage IV: M1a) melanoma considered incurable by Standard of Care. For metastatic melanoma, only distal cutaneous, subcutaneous, or lymph node metastases are allowed.
8. Previously exposed to ICI(s) and be categorized following the SITC Immunotherapy Resistance Taskforce meeting one of the following:

   a. Have primary resistance: PD-(L)-1 inhibitor exposure ≥6 weeks and have the best response as one of the following: i. PD, ii. SD for \<6 months. b. Have secondary resistance: PD-(L)-1 inhibitor exposure ≥6 weeks and best response CR, PR, or SD \>6 months.

   c. Have adjuvant therapy resistance: recurrence subcategorized into primary resistance/early relapse occurred \<12 weeks after the last dose, and late relapse occurred ≥12 weeks after the last dose. If BRAF mutated, patients must have progressed to treatment with BRAF inhibitors.

   d. Have neoadjuvant therapy resistance including subjects with or without major pathologic response and subsequent PD that fulfills criteria for primary or secondary resistance e. Discontinued from ICI(s) therapy due to immune-related adverse events grade 3 or 4 other than endocrine insufficiencies treatable with hormonal replacement therapy, and meet one of the following: i. Remain on SD at discontinuation of PD-(L)1 inhibitor in combination with ipilimumab or show regrowth after \<12 weeks of the last dose ii. Have not achieved a CR with single-agent PD-(L)1 inhibitor or combination of PD-(L)1 with LAG-3 inhibitor
9. At least 1 non-ulcerated lesion, not exceeding 5 cm in (the longest) diameter, for intratumoral injection(s) and measurable as defined by iRECIST.
10. Resolution of toxicity due to prior therapy returned to baseline or \< Grade 2, except for alopecia or other irreversible immune-mediated AEs, as defined by CTCAE v5.0. and SITC ICI-related AEs.
11. Prior treatment(s) delivered by IT injection to the to-be injected lesion(s), including investigational agents, is allowed.

    For Phase I and Phase IIa Arms A, C, and D in addition:
12. Age ≥ 18 years.
13. Estimated life expectancy of at least 3 months.
14. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
15. Resolution of toxicity due to prior therapy to Grade \< 2 (except for alopecia and transaminases in case of liver metastases) as defined by CTCAE v5.0.
16. Ability to give written informed consent and to comply with the protocol.
17. All subjects of childbearing potential (defined as \< 2 years after last menstruation or not surgically sterile) must have a negative highly sensitive pregnancy test at screening (urine/serum) and agree to use highly effective method for contraception according to the EU Clinical Trial Facilitation Group guidance from time of signing the informed consent form (ICF) until at least 120 days after the last administration of CyPep-1. The partners of subjects with childbearing potential must also apply contraceptive methods and are recommended not to donate sperm.
18. Adequate bone marrow, liver, and renal function:

    1. Platelet count ≥ 100 x 109/L
    2. Hemoglobin ≥ 6.0 mmol/L or 9.67 g/dL
    3. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    4. Total bilirubin ≤ 1.5 x ULN, except for subjects with familial bilirubinemia (Gilbert's disease)
    5. Serum ASAT and ALAT ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastases)
    6. Creatinine clearance ≥ 30 mL/min (by CKD-EPI formula).

    For Phase IIa Arm B:

    Participants are eligible to be included in Arm B of the trial only if all of the following criteria apply:
19. The participant provides written informed consent for the trial.
20. Be ≥ 18 years of age on day of signing informed consent.
21. Participant with histologically or cytologically confirmed diagnosis of advanced (unresectable Stage III) or metastatic (Stage IV) solid tumor malignancy (including lymphomas) that is refractory to standard-of-care treatment or for which there is no standard therapy considered appropriate. Metastatic deposits (including cutaneous/subcutaneous lesions and metastatic deposits in lymph nodes) of tumors for which IT injections may be performed are eligible. Pure cutaneous infiltrations (e.g., breast cancer cutaneous carcinomatosis) are ineligible.
22. Subjects must have progressed on treatment with an anti-PD1/L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies. Treatment progression is defined by meeting all of the following criteria:

    1. Has received at least 2 doses of an approved anti-PD-1/L1 mAb.
    2. Has demonstrated clinical or radiological disease progression (PD) after PD-1/L1
23. A male participant must agree to use contraception and refrain from sperm donation during the treatment period and for at least 120 days after the last dose of trial medication.
24. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP)
    2. A WOCBP (defined as \< 2 years after last menstruation or not surgically sterile) must have a negative highly sensitive pregnancy test at screening (urine/serum) and must follow contraceptive guidance (highly effective method for contraception according to the EU Clinical Trial Facilitation Group guidance) from time of signing the ICF until at least 120 days after the last administration of trial medication. The partners of subjects with childbearing potential must also apply contraceptive methods and are recommended not to donate sperm.
25. 1 to 3 non-ulcerated transcutaneously accessible lesion(s) for injection and measurable as defined by iRECIST. All other tumor lesion(s) may be selected for efficacy follow-up but will not be subjected to treatment with CyPep-1.
26. Presence of tumor lesion(s) (that have not been previously irradiated) suitable for biopsy at screening and at Week 6.
27. Have an ECOG performance status of 0 to 1.
28. Have adequate organ function as defined in the following table. Specimens must be collected within 10 days (or less) prior to the start of trial treatment.
29. Only for subjects with lymphoma: have measurable disease defined as at least one lesion that can be accurately measured in at least two dimensions with spiral CT scan. Minimum measurement must be \> 15 mm in the longest diameter by \> 10 mm in the short axis.
30. Estimated life expectancy of at least 3 months.
31. HIV infected participants must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease.

Exclusion criteria:

For Phase I and Phase IIa Arms A, C, and D: subjects who meet ANY of the following criteria at screening will be excluded from trial entry:

1. There is no limit to the number of prior treatment regimens, but prior treatment(s) should not include compounds delivered by IT injection to the to-be injected lesion(s), including investigational agents. Subjects with prior IT therapies are allowed in Arm D.
2. Participation in another clinical trial within 4 weeks prior to first dose of CyPep-1.
3. Anti-cancer therapy within 4 weeks prior to the first dose of CyPep-1 (within 2 weeks for palliative radiotherapy, within 1 week for endocrine therapy).
4. Major surgical procedure within 14 days prior to the first dose of CyPep-1.
5. Live vaccine within 30 days prior to first dose of CyPep-1.
6. Expected to require any other form of systemic or localized antineoplastic therapy while in this trial. Localized palliative radiotherapy for pain relief is allowed on tumor lesions that are not selected for evaluation of treatment response.
7. Clinical evidence of an active second malignancy that is progressing or requires active treatment, except for curatively treated early stage (carcinoma in situ or stage 1) carcinomas or non-melanoma skin cancer.
8. Active autoimmune disease requiring immunosuppressive therapy.
9. Any condition requiring continuous systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive agents within 2 weeks prior to first dose of CyPep-1. Inhaled, intranasal or topical (only on areas outside the injected lesion\[s\]) and physiological replacement doses of up to 10 mg daily prednisone equivalent are permitted in the absence of active auto-immune disease.
10. Abnormal or clinically significant coagulation parameters:

    1. Prothrombin Time - International Normalized Ratio (PT-INR) ≥ 1.5 ULN
    2. Activated Partial Thromboplastin Time (APTT) ≥ 1.5 ULN Subjects being treated with anticoagulants are excluded if the coagulation parameters are outside the therapeutic intervals as described in the SmPC for the administered treatment.
11. Subjects on anticoagulants with temporarily stop and start, supported by low molecular weight heparin (or other anticoagulation therapy at the discretion of the investigator and/or per local standard of care) during treatment period.
12. Known hypersensitivity to any component of CyPep-1.
13. Prior allogeneic tissue/solid organ transplant, stem cell or bone marrow transplant.
14. Known active human immunodeficiency virus (HIV). Subject is eligible when normal levels of CD4 are present.
15. Central nervous system (CNS) metastasis that is symptomatic or progressing or that requires current therapy (e.g., evidence of new or enlarging CNS metastasis, carcinomatous meningitis or new neurological symptoms attributable to CNS metastasis).
16. QTcF \> 480 ms, history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation, or Torsade de Pointes.
17. Women who are pregnant or breastfeeding.
18. Any serious and/or unstable pre-existing medical, psychiatric or other condition which in the investigator's opinion could interfere with subject safety, obtaining written informed consent, or compliance with the trial protocol.

    Additional exclusion criteria for Phase IIa Arm C:
19. Subject is a candidate for hepatic surgery or local regional therapy of liver metastases with curative intent.
20. More than one third of the liver is estimated to be involved with metastases.
21. There is invasion by cancer into the main blood vessels such as the portal vein, hepatic vein or the vena cava.
22. Subject is currently receiving or has received liver metastatic-directed therapy (eg: radiation, ablation, embolization) less than 4 weeks prior to enrolmentor hepatic surgery.

    Exclusion criteria specific for Phase IIa Arm B:

    Participants are excluded from the trial if ANY of the following criteria apply at screening:
23. A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to trial treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
24. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA 4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher irAE.
25. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks (within 1 week for endocrine therapy) prior to first dose of CyPep-1.
26. Has received prior (palliative) radiotherapy within 2 weeks of start of trial treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
27. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of CyPep-1. Note: Administration of killed vaccines are allowed.
28. Has received prior compounds delivered by IT injection to the to-be injected lesion(s), including investigational agents.
29. Expected to require any other form of systemic or localized antineoplastic therapy while in this trial. Localized palliative radiotherapy for pain relief is allowed on tumor lesions that are not selected for evaluation of treatment response.
30. Ongoing pembrolizumab-related toxicity event(s) as per TLT definition.
31. Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment.
32. Has had an allogeneic tissue/solid organ transplant.
33. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of CyPep-1.
34. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years, except for curatively treated early stage (carcinoma in situ or stage 1) carcinomas or non-melanoma skin cancer.

    Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
35. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
36. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients or to another mAb, as well as any known hypersensitivity to any component of CyPep-1.
37. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
38. Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
39. Has an active infection requiring systemic therapy.
40. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
41. Has a known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection.
42. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
43. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
44. Has received radiation therapy to the lung that is \>30 Gy within 6 months of the first dose of trial treatment (applicable only for subjects with non-small cell lung cancer \[NSCLC\], mesothelioma and small cell lung cancer \[SCLC\]).

Primary outcomes:
measure: Type and number of adverse events (AEs)
timeFrame: 2 weeks
measure: Dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) for determination of RP2D of CyPep-1
timeFrame: 6 weeks
Secondary outcomes:
measure: Objective response rate (ORR) at RP2D in injected lesions
timeFrame: 8 weeks
Other outcomes:
measure: Progression-free survival (PFS) based on all lesions
timeFrame: 8 weeks
measure: Overall survival (OS)
timeFrame: 3 months
Locations:
city: Paris
country: France
facility: Institue Curie
city: Villejuif
country: France
facility: Institute Gustave Roussy
city: Amsterdam
country: Netherlands
facility: NKI/AvL
city: Leiden
country: Netherlands
facility: LUMC
city: Rotterdam
country: Netherlands
facility: EMC
city: Utrecht
country: Netherlands
facility: UMCU
city: Barcelona
country: Spain
facility: Vall d'Hebron (VHIO)
city: Madrid
country: Spain
facility: START
Study officials:
References:
citation: Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5.
citation: Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
citation: Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.
citation: Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
citation: Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015 Apr 3;348(6230):69-74. doi: 10.1126/science.aaa4971.
citation: Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19. Erratum In: N Engl J Med. 2018 Nov 29;379(22):2185. doi: 10.1056/NEJMx180040.
citation: Szczepanski C, Tenstad O, Baumann A, Martinez A, Myklebust R, Bjerkvig R, Prestegarden L. Identification of a novel lytic peptide for the treatment of solid tumours. Genes Cancer. 2014 May;5(5-6):186-200. doi: 10.18632/genesandcancer.18.
citation: Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci. 2013 May;1284(1):1-5. doi: 10.1111/nyas.12105.
citation: Zappasodi R, Merghoub T, Wolchok JD. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell. 2018 Apr 9;33(4):581-598. doi: 10.1016/j.ccell.2018.03.005.
citation: Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.